Cardiomyocyte (CM) proliferative potential varies considerably across species. While lower vertebrates and neonatal mammals retain robust capacities for CM proliferation, adult mammalian CMs lose proliferative potential due to cell-cycle withdrawal and polyploidization, failing to mount a proliferative response to regenerate lost CMs after cardiac injury. The decline of murine CM proliferative potential occurs in the neonatal period when the endocrine system undergoes drastic changes for adaptation to extrauterine life. We recently demonstrated that thyroid hormone (TH) signaling functions as a primary factor driving CM proliferative potential loss in vertebrates. Whether other hormonal pathways govern this process remains largely unexplored. Here we showed that agonists of glucocorticoid receptor (GR) and vitamin D receptor (VDR) suppressed neonatal CM proliferation in vitro. We next examined CM nucleation and proliferation in mutant mice lacking GR or VDR specifically in CMs, but we observed no difference between mutant and control littermates. Additionally, we generated compound mutant mice that lack GR or VDR and express dominant-negative TH receptor alpha in their CMs, and similarly observed no increase in CM proliferative potential compared to dominant-negative TH receptor alpha mice alone. Thus, although GR and VDR activation in cultured CMs is sufficient to inhibit CM proliferation, they seem to be dispensable for CM cell-cycle exit and binucleation in vivo. In addition, given the recent report that VDR activation in zebrafish promotes CM proliferation and tissue regeneration, our results suggest distinct roles of VDR in zebrafish and rodent CM cell-cycle regulation.
dosed with propylthiouracil (PTU) -a potent inhibitor of TH synthesis -from birth through postnatal day 14 (P14) show significantly increased mononuclear CM percentage and CM proliferation 11 . These mononuclear CMs and CM proliferation phenotypes are also observed in mutant mice in which TH signaling is specifically inactivated in CMs 11 . These mutant mouse hearts also display enhanced recovery after MI as indicated by cardiac contractile functions and fibrosis one month post-surgery. Conversely, exogenous TH suppresses CM proliferation and cardiac regeneration in adult zebrafish. These data strongly suggest an inhibitory role played by TH in the developmental control of CM proliferative potential.
In addition to TH, other hormones such as glucocorticoids and vitamin D have been shown to suppress CM proliferation in culture. Glucocorticoids are stress-associated steroid hormones produced by the adrenal glands that act on nearly all organs in the body via binding to the glucocorticoid receptor (GR) 17, 18 . Specifically, glucocorticoids like dexamethasone are established cell cycle regulators known to repress the cell cycle primarily through the GR, which acts as a transcription factor after glucocorticoid binding 19, 20 . It has been reported that GR activation inhibits neonatal rat CM proliferation and increases CM binucleation through epigenetic repression of Cyclin D2 gene 21, 22 . Furthermore, adult zebrafish heart regeneration is impaired by either GR agonist exposure 23 or crowding-induced stress through GR activation 24 .
Vitamin D is a steroid hormone precursor that is hydroxylated sequentially in the liver and kidneys into ercalcitriol (D2) or calcitriol (D3). These active hormones can bind to vitamin D receptors (VDRs) and regulate downstream gene expression in target cells 25 . Alfacalcidol (Alfa) is a vitamin D analog that forms calcitriol directly after hydroxylation in the liver 26 . Antiproliferative effects of vitamin D analogs have been reported in mammalian cells generally 27 and mammalian CMs and CM-derived cell lines specifically 28, 29 . However, vitamin D analogs alfacalcidol and calcipotriene significantly increase CM proliferation in embryonic zebrafish, whereas VDR-inhibitor PS121912 significantly decreases CM proliferation 30 . Alfacalcidol also stimulates CM proliferation in adult zebrafish during heart regeneration, while VDR suppression decreases CM proliferation during regeneration 30 .
Intriguingly, CM-specific deletion of either GR or VDR results in cardiac hypertrophy 31, 32 .
This cardiac enlargement phenotype together with the documented functions to inhibit CM proliferation in vitro led us to investigate the possibility that GR and VDR signaling alters CM proliferative potential in vivo either alone or in combination with TH signaling activation.
RESULTS
We first examined if GR and VDR activation regulates CM proliferation in vitro. Primary CMs were isolated from neonatal mice and cultured with three GR agonists hydrocortisone, corticosterone, and dexamethasone for 48 hours. Proliferating CM nuclei were positive for DAPI (blue), PCM-1 rings (green), and EdU incorporation (red) ( Fig. 1 ). CM proliferation is inhibited by hydrocortisone (0.30  0.03%), corticosterone (0.15  0.1%), and dexamethasone (0.07  0.09%) as compared to CMs cultured without any GR agonists (1.22  0.44%) ( Fig. 1A ). We also cultured primary neonatal mouse CMs with two VDR agonists: calcitriol and alfacalcidol.
Neonatal CM proliferation was inhibited by 1 μM calcitriol (0.35  0.07%) and 1 μM alfacalcidol (0.40  0.02%) relative to CMs cultured without any VDR agonists (1.11  0.11%) ( Fig. 1B ). This in vitro suppression of CM proliferation led us to investigate the in vivo contribution of GR and VDR to cardiomyocyte proliferative potential.
To elucidate the physiological role of GR in regulating CM proliferative potential in vivo, we generated Myh6-Cre;Gr f/f knockout mice in which CM-specific CRE recombinase (Myh6-Cre) deletes the Gr gene (also named as Nuclear Receptor Subfamily 3 Group C member 1, Nr3c1), resulting in CM-specific loss of GR signaling ( Fig. 2A ). We examined heart phenotypes at P14 when mouse CMs have completed binucleation and withdrawn from the cell cycle 7 . Interestingly, unlike our in vitro primary CMs, no changes of CM proliferative activity in vivo were observed at P14 ( Fig. 2B-D ). Myh6-Cre;Gr f/f knockout mice did not show an increase in the heart weight (mg) to body weight (g) ratio (6.21  0.16) compared to littermate controls (6.16  0.18) ( Fig. 2B ).
Additionally, P14 Myh6-Cre;Gr f/f hearts were comparable to littermate control hearts in terms of mononuclear CM percentage (13.6  1.1% vs 13.7  2.0%) ( Fig. 2C ). Analysis of CM proliferation using the Ki67 marker also showed a no increase in Ki67 + CMs in mutant hearts (2.1  0.7% vs 2.2  0.3%) ( Fig. 2D ). Altogether, we did not observe that CM-specific loss of GR affects CM proliferative potential.
To investigate the contribution of VDR to the control CM proliferative potential in vivo, we generated mice with CM-specific loss of VDR (Myh6-Cre;Vdr f/f ) ( Fig. 3A ). As with GR deletion, no changes in CM proliferative activity were observed at P14 ( Fig. 3B -D). The heart weight to body weight ratio did not significantly differ between Myh6-Cre;Vdr f/f knockout mice We recently showed that TH signaling regulates CM proliferative potential, but mice with deficiency in TH receptor activation in CMs have ~30% mononuclear CMs at P14, implicating the existence of other pathways that contribute to CM binucleation in the neonatal period 11 . We next investigated whether loss of GR or VDR signaling affect CM proliferative potential in combination with loss of TH signaling. We bred Myh6-Cre;Thra DN/+ ;Gr f/f mice that express dominant negative TH receptor alpha (THRA DN ) and delete Gr specifically in CMs (Fig. 4A ). The heart weight to body weight ratio for Myh6-Cre;Thra DN/+ ;Gr f/f (7.28  0.05) did not significantly differ from littermate Myh6-Cre;Thra DN/+ ;Gr f/+ controls (7.61  0.55) ( Fig. 4B ). Additionally, compound mutant hearts did not display significant increases in CM proliferation (3.5  0.7% vs 3.2  0.7%) or CM nucleation (32.7  8.7% vs 33.4  6.1%) compared to littermate Myh6-Cre;Thra DN/+ ;Gr f/+ controls at P14 (Fig. 4C,D) . Thus, we did not observe any significant effect of GR loss on top of TH signaling suppression.
Finally, we bred Myh6-Cre;Thra DN/+ ;Vdr f/f mice and observed no significant difference in the heart weight to body weight ratio (6.83  0.14 vs 7.23  0.83), CM nucleation (24.4  2.3% vs 26.9  3.4%), or CM proliferation (3.0  0.3 vs 3.9  1.0%) compared to Myh6-Cre;Thra DN/+ ;Vdr f/+ littermate controls ( Fig. 5A-D) . As such, we did not observe a significant effect of VDR loss on CM proliferative potential on top of TH signaling suppression. Overall, our results show that although GR and VDR activation in cultured CMs is sufficient to inhibit CM proliferation, they seem to be dispensable for CM cell-cycle exit and binucleation in vivo.
DISCUSSION
Mammalian cardiomyocytes undergo postnatal cell-cycle exit and polyploidization when they lose regenerative potential 7, 8, [33] [34] [35] . The intrinsic and extrinsic molecular drivers of this process have been under intensive studies 4, [36] [37] [38] [39] [40] . Our observation that both glucocorticoids and vitamin D inhibit proliferation of primary neonatal mouse CMs in vitro is consistent with previous reports in culture 21, 22, 28, 29, 41 . GR activation inhibits neonatal rat CM proliferation and increases CM binucleation 21, 22 . Vitamin D treatment reduces expression of c-myc and proliferating cell nuclear antigen, and blocks cell proliferation in rat CM culture 41 .
Our in vivo analysis, however, did not reveal a significant role for either receptor in regulating postnatal CM proliferative potential loss: neither CM nucleation nor CM proliferation was influenced by either GR or VDR loss in P14 mice. As such, while GR and VDR signaling are sufficient to inhibit CM proliferation in culture, we did not observe their regulatory influence on CM proliferative potential to be determinative in vivo. Moreover, we didn't observe cardiac hypertrophy of these mutant mice at P14, suggesting that the hypertrophic phenotypes described in both mutant mice 31, 32 develop later in the postnatal life. Nevertheless, the discrepancy between our in vitro and in vivo data could be explained if there are in vivo factors not present in vitro whose regulatory influence over CM proliferative potential is strong enough to mask any contributions from either GR or VDR signaling.
One such factor could be thyroid hormones (THs). We previously established a potent inhibitory role for TH signaling over CM proliferative potential 11 . Still, this still left open the possibility that GR or VDR signaling may alter the observed effects of loss of TH signaling on CM proliferative potential. When we analyzed mice both expressing dominant negative TH receptor alpha and lacking either GR or VDR in their CMs, no significant effects of either GR or VDR loss were detected. In other words, the regulatory influence of TH over CM proliferative potential is strong enough to overpower any contributions from either GR or VDR. Further investigation is needed to explore the molecular and endocrine factors that act in parallel to and downstream of thyroid hormone to establish vertebrate cardiac regenerative potential. In sum, our results suggest that GR and VDR don't function as major triggers of postnatal CM cell-cycle withdrawal and binucleation in vivo. Possible explanations could involve the physiological levels of these hormones that might not be high enough, and possible other regulatory mechanisms that prevent the action of GR and VDR in vivo.
It is worth noting that VDR signaling may have distinct regulatory roles across vertebrates.
It is reported recently that in zebrafish, VDR activation stimulates CM proliferation, while VDR antagonism reduces CM proliferation and compromises cardiac regeneration 30 . This sharply contrasts with VDR signaling in mammals, which seems to exert broadly anti-proliferative effects [27] [28] [29] , as corroborated by our in vitro observations. It would be interesting to unravel the differential roles of VDR and underlying mechanisms on cell cycle activity across phylogeny. Analysis of cardiomyocyte nucleation: Ventricular tissues were fixed in 3.7% paraformaldehyde for 48 hours followed by incubation in 50% w/v potassium hydroxide solution overnight. After a brief wash with PBS, tissues were gently crushed to release dissociated cardiomyocytes. Cells were further washed with PBS three times, deposited on slides, and then allowed to dry out completely. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). 
MATERIALS & METHODS

Animals
